Q-omics provides the consensus-scored IL17RC profile across patient tissues and cancer cell-line models. IL17RC expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, IL17RC is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, IL17RC RNA expression shows 17,154 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UVM, HNSC, and TGCT as cancer lineages where IL17RC shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IL17RC — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IL17RC survival associations across molecular data types. IL17RC RNA expression shows survival associations in the most cancer types (22), followed by mutation status (2) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IL17RC RNA expression–survival associations across cancer types. High IL17RC expression shows unfavorable associations in LGG and KICH, but favorable associations in UVM, COAD, ACC and KIRP. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .004). Together, the overview and detailed table identify UVM as the clearest survival context for IL17RC RNA expression.
This table summarizes IL17RC tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for IL17RC. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IL17RC shows lower tumor expression in HNSC, KICH, BLCA, THCA, LUSC and CHOL. The HNSC box plot shows higher IL17RC RNA expression in normal versus tumor tissue (log2 FC = −0.791, t-test p < 0.001).
This table shows molecular features associated with IL17RC in patient tissues and cancer cell lines. In patient samples, IL17RC shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, IL17RC RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
